TRIL
Income statement / Annual
Last year (2020), Trillium Therapeutics Inc.'s total revenue was $148,000.00,
an increase of 19.35% from the previous year.
In 2020, Trillium Therapeutics Inc.'s net income was -$59.35 M.
See Trillium Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
| Operating Revenue |
$148,000.00
|
$124,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$147,852.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$148.00 |
$124,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$25.35 M
|
$25.30 M
|
$31.88 M
|
$29.53 M
|
$22.16 M
|
$13.01 M
|
$9.13 M
|
$3.13 M
|
$626,788.00
|
$818,290.00
|
| General & Administrative
Expenses |
$36.26 M
|
$4.31 M
|
$2.63 M
|
$3.07 M
|
$2.93 M
|
$2.29 M
|
$2.22 M
|
$903,669.00
|
$468,710.00
|
$1.41 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$36.26 M
|
$4.31 M
|
$2.63 M
|
$3.07 M
|
$2.93 M
|
$2.29 M
|
$2.22 M
|
$903,669.00
|
$468,710.00
|
$1.41 M
|
| Other Expenses |
$0.00 |
$3.01 M |
$0.00 |
-$0.00 |
$0.00 |
$0.00 |
-$0.00 |
$0.00 |
$0.00 |
$902,082.00 |
| Operating Expenses |
$61.60 M |
$32.61 M |
$34.51 M |
$32.60 M |
$25.09 M |
$15.30 M |
$11.35 M |
$4.04 M |
$1.10 M |
$3.13 M |
| Cost And Expenses |
$61.60 M |
$35.56 M |
$34.51 M |
$32.60 M |
$25.09 M |
$15.30 M |
$11.35 M |
$4.04 M |
$1.10 M |
$3.13 M |
| Interest Income |
$2.01 M |
$614,000.00 |
$795,870.00 |
$574,155.00 |
$310,629.00 |
$352,013.00 |
$326,216.00 |
$41,429.00 |
$25,873.00 |
$35,661.00 |
| Interest Expense |
$0.00 |
$177,000.00 |
$31,570.00 |
$54,075.00 |
$48,634.00 |
$52,887.00 |
$60,101.00 |
$37,691.00 |
$0.00 |
$14,031.00 |
| Depreciation &
Amortization |
$591,000.00
|
$2.11 M
|
$2.31 M
|
$3.74 M
|
$3.19 M
|
$329,858.00
|
$566,807.00
|
$609,323.00
|
$6,415.17
|
$250,352.00
|
| EBITDA |
-$58.65 M
|
-$39.31 M
|
-$28.85 M
|
-$32.05 M
|
-$23.11 M
|
-$10.23 M
|
-$10.47 M
|
-$3.38 M
|
-$1.06 M
|
-$2.84 M
|
| EBITDA Ratio |
-396.3 |
-317.02 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-415.24
|
-285.79
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$2.21 M
|
-$6.16 M
|
$3.33 M
|
-$3.25 M
|
-$1.26 M
|
$4.69 M
|
$251,062.00
|
$9,014.15
|
$28,480.00
|
$0.00
|
| Income Before Tax |
-$59.24 M |
-$41.59 M |
-$31.19 M |
-$35.85 M |
-$26.35 M |
-$10.61 M |
-$11.10 M |
-$4.03 M |
-$1.07 M |
$0.00 |
| Income Before Tax Ratio
|
-400.3
|
-335.44
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$102,000.00 |
$28,000.00 |
$5,873.59 |
$3,180.91 |
-$2.74 M |
$6,847.35 |
$311,164.00 |
$46,705.00 |
$28,480.00 |
$14,031.00 |
| Net Income |
-$59.35 M |
-$41.62 M |
-$31.19 M |
-$35.86 M |
-$23.61 M |
-$10.62 M |
-$11.10 M |
-$4.03 M |
-$1.07 M |
-$3.11 M |
| Net Income Ratio |
-400.99 |
-335.66 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.71 |
-1.65 |
-2.24 |
-3.67 |
-3.02 |
-1.6 |
-2.64 |
-2.97 |
-17.15 |
-5.11 |
| EPS Diluted |
-0.71 |
-1.65 |
-2.24 |
-3.67 |
-3.02 |
-1.6 |
-2.64 |
-2.97 |
-17.15 |
-5.11 |
| Weighted Average Shares
Out |
$83.75 M
|
$25.26 M
|
$13.91 M
|
$9.77 M
|
$7.82 M
|
$6.64 M
|
$4.20 M
|
$1.36 M
|
$62,205.00
|
$608,258.00
|
| Weighted Average Shares
Out Diluted |
$83.75 M
|
$25.26 M
|
$13.91 M
|
$9.77 M
|
$7.82 M
|
$6.64 M
|
$4.20 M
|
$1.36 M
|
$62,205.00
|
$608,258.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
